When ACE Inhibitor Treatment Has Not Achieved Adequate Proteinuria Reduction in Males with X-Linked Alport Syndrome

Clinical Scenario

This protocol addresses males with X-linked Alport syndrome — a population requiring lifelong nephrology follow-up with optimisation of risk factors for progressive renal failure, including careful management of hypertension, proteinuria, and dyslipidaemia.

Prior Line & Reason for Escalation

Initial management centres on treatment with ACE inhibitors, initiated even before the onset of proteinuria in those with high-risk genetic mutations or a family history consistent with early-onset renal failure, combined with careful control of hypertension, proteinuria, and dyslipidaemia. When this approach does not achieve sufficient reduction in proteinuria, a next-line strategy is indicated.

Next-Line Approach (Partial Overview)

Once ACE inhibitor therapy alone proves insufficient, additional agents with antiproteinuric activity are introduced, targeting the renin-angiotensin-aldosterone pathway, with the clinical goal of further reduction in proteinuria.

The complete regimen — specific agents, sequencing, and monitoring parameters — is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Males with X-linked Alport syndrome should be managed lifelong by a nephrologist and have their risk factors for progressive renal failure optimized, including careful management of hypertension, proteinuria, and dyslipidemia.
Angiotensin-receptor blockers and aldosterone inhibitors have additional benefits for proteinuria.

DOI: 10.1681/ASN.2012020148

View source ↗